WallStreetZenWallStreetZen

NASDAQ: MGTX
Meiragtx Holdings PLC Stock Forecast, Predictions & Price Target

Analyst price target for MGTX

Based on 1 analyst offering 12 month price targets for Meiragtx Holdings PLC.
Min Forecast
$11.00+134.54%
Avg Forecast
$11.00+134.54%
Max Forecast
$11.00+134.54%

Should I buy or sell MGTX stock?

Based on 1 analyst offering ratings for Meiragtx Holdings PLC.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MGTX stock forecasts and price targets.

MGTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-15

1 of 1

Forecast return on equity

Is MGTX forecast to generate an efficient return?
Company
52.3%
Industry
76.1%
Market
79%
MGTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MGTX forecast to generate an efficient return on assets?
Company
20.59%
Industry
30.96%
MGTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MGTX earnings per share forecast

What is MGTX's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$1.53
Avg 2 year Forecast
$0.87
Avg 3 year Forecast
$0.18

MGTX revenue forecast

What is MGTX's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$51.7M+7,317.07%
Avg 2 year Forecast
$269.6M+38,582.93%
Avg 3 year Forecast
$334.0M+47,825.39%
MGTX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MGTX revenue growth forecast

How is MGTX forecast to perform vs Biotechnology companies and vs the US market?
Company
702.06%
Industry
35%
Market
9.85%
MGTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MGTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MGTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MGTX$4.69$11.00+134.54%Buy
TNYA$3.81$18.00+372.44%Strong Buy
IMMP$2.56$10.00+290.63%Buy
SLDB$7.93$20.00+152.21%Strong Buy
INZY$5.00$16.40+228.00%Strong Buy

Meiragtx Holdings Stock Forecast FAQ

Is Meiragtx Holdings Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: MGTX) stock is to Buy MGTX stock.

Out of 1 analyst, 0 (0%) are recommending MGTX as a Strong Buy, 1 (100%) are recommending MGTX as a Buy, 0 (0%) are recommending MGTX as a Hold, 0 (0%) are recommending MGTX as a Sell, and 0 (0%) are recommending MGTX as a Strong Sell.

If you're new to stock investing, here's how to buy Meiragtx Holdings stock.

What is MGTX's earnings growth forecast for 2024-2026?

(NASDAQ: MGTX) Meiragtx Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.61%.

Meiragtx Holdings's earnings in 2024 is -$74,105,000.On average, 2 Wall Street analysts forecast MGTX's earnings for 2024 to be -$98,067,585, with the lowest MGTX earnings forecast at -$113,822,705, and the highest MGTX earnings forecast at -$82,312,465. On average, 2 Wall Street analysts forecast MGTX's earnings for 2025 to be $55,946,753, with the lowest MGTX earnings forecast at $41,156,232, and the highest MGTX earnings forecast at $70,737,274.

In 2026, MGTX is forecast to generate $11,575,190 in earnings, with the lowest earnings forecast at $11,575,190 and the highest earnings forecast at $11,575,190.

What is MGTX's revenue growth forecast for 2024-2026?

(NASDAQ: MGTX) Meiragtx Holdings's forecast annual revenue growth rate of 702.06% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.85%.

Meiragtx Holdings's revenue in 2024 is $697,000.On average, 1 Wall Street analysts forecast MGTX's revenue for 2024 to be $3,324,458,972, with the lowest MGTX revenue forecast at $3,324,458,972, and the highest MGTX revenue forecast at $3,324,458,972. On average, 1 Wall Street analysts forecast MGTX's revenue for 2025 to be $17,338,348,997, with the lowest MGTX revenue forecast at $17,338,348,997, and the highest MGTX revenue forecast at $17,338,348,997.

In 2026, MGTX is forecast to generate $21,480,981,007 in revenue, with the lowest revenue forecast at $21,480,981,007 and the highest revenue forecast at $21,480,981,007.

What is MGTX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: MGTX) forecast ROA is 20.59%, which is lower than the forecast US Biotechnology industry average of 30.96%.

What is MGTX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year MGTX price target, the average MGTX price target is $11.00, with the highest MGTX stock price forecast at $11.00 and the lowest MGTX stock price forecast at $11.00.

The Wall Street analyst predicted that Meiragtx Holdings's share price could reach $11.00 by Mar 15, 2025. The average Meiragtx Holdings stock price prediction forecasts a potential upside of 134.54% from the current MGTX share price of $4.69.

What is MGTX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: MGTX) Meiragtx Holdings's current Earnings Per Share (EPS) is -$1.17. On average, analysts forecast that MGTX's EPS will be -$1.53 for 2024, with the lowest EPS forecast at -$1.77, and the highest EPS forecast at -$1.28. On average, analysts forecast that MGTX's EPS will be $0.87 for 2025, with the lowest EPS forecast at $0.64, and the highest EPS forecast at $1.10. In 2026, MGTX's EPS is forecast to hit $0.18 (min: $0.18, max: $0.18).

What is MGTX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: MGTX) forecast ROE is 52.3%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.